Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697159 | 0.88 | NPC1 (0.58) | ALDH1A1SMN1; SMN2NPC1TDP1HTR2A | |
| SCHEMBL5542274 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2NPC1TDP1FKBP1A | |
| SCHEMBL7509584 | 0.86 | HTR2A (0.50) | ALDH1A1SMN1; SMN2FKBP1AHTR2AOPRM1 | |
| SCHEMBL5538867 | 0.86 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NPC1TDP1FKBP1A | |
| SCHEMBL5536072 | 0.86 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NPC1TDP1FKBP1A | |
| SCHEMBL7515241 | 0.85 | HTR2A (0.49) | ALDH1A1SMN1; SMN2FKBP1AHTR2AOPRM1 | |
| SCHEMBL7516751 | 0.85 | HTR2A (0.49) | ALDH1A1SMN1; SMN2FKBP1AHTR2AOPRM1 | |
| SCHEMBL5546208 | 0.82 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2NPC1TDP1FKBP1A | |
| SCHEMBL7330398 | 0.82 | HRH3 (0.60) | ALDH1A1SMN1; SMN2NPC1HTR2AOPRM1 | |
| SCHEMBL7509167 | 0.81 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2NPC1HTR2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544987-B2 | Pyrrolidine or piperidine sulfonyl compounds; stimulate neurite outgrowth in nerve cells leading to nerve regeneration for treatment of hair loss, memory loss or vision disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1237869-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001040185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | NGF, GAP43, BDNF | ALDH1A1 3381/4885SMN1; SMN2 17/4885NPC1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.